3rd ESTRO Forum 2015 S265 to define margins to account for these residual uncertainties. By shortening treatment time e.g. by the use of VMAT, we expect the intra-fraction cervix-uterus motion to decrease.
Conclusions:
DIBH is a feasible approach for locally advanced NSCLC. The intra-fractional reproducibility of the tumour position remained high during the whole RT course, provided daily image guidance with tumour match is applied. Additional benefit of DIBH was absence of differential motion between the primary tumour and the mediastinal lymph nodes.
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Purpose/Objective:
To systematically evaluate the effectiveness of re-scanning for the Varian ProBeam PBS proton therapy system in the context of liver tumour treatments Materials and Methods: 3 deformable motions (mean amplitude of 8/15/20mm, corresponding to Motion A/B/C in figure 1) were extracted from a 4DMRI library (Siebenthal et al 2007, Phys. Med. Biol. 52; Boye et al 2013, Med. Phys. 40) and respectively applied to 3 different liver patient geometries with varying tumour volumes (100/200/400ccm). Reference 3D plans were first calculated to patient specific ITV's (2Gy RBE ) using spot spacing of 4/8mm for both 1-and 3field plans. 4D dose calculations were then performed for both regular and irregular motions, each with 4 different starting phases. For each scenario, 1-19 times adaptivescaled, layered and volumetric rescanning were simulated using the beam profiles, scanning dynamics and beam currents of the Varian ProBeam system. In addition, 4 energy switching times (700/500/200/100ms) were modelled. All 4D dose distributions were assessed by means of the D5-D95 metric in the CTV. Results: In total, more than 100 thousand 4D calculations have been performed, covering 10 different patient, motion and dose delivery variables. Regardless of patient geometry and motion regularity, the 3-field plans can achieve D5-D95 values within 6.5% of the static values without any re-scanning for motions up to 8mm (motion A), which can be further reduced to 2% if 10x rescanning is applied per field (see results of one example patient case in figure 1). For larger motions, given the same rescan#, volumetric rescanning results in 5% better homogeneity than layered, but requires 6.5 times longer treatment time (for 700ms energy changes). Layered re-scanning can at best achieve homogeneity within about 10% of those of the static case, while volumetric rescanning gets to within 5%, but is extremely case and rescan# specific. By reducing the energy switching time, treatment times can decrease by 68% for volumetric re-scanning (100ms energy changes), but with no further improvements on D5-D95. Motion irregularity has pronounced influence only on the two large motions (B and C) but generally has more effect on volumetric re-scanning than layered re-scanning.
Conclusions:
For larger motions, layered re-scanning has been shown to be the most time efficient, whereas volumetric rescanning is more effective for retrieving dose homogeneity. However, for motions below 8mm, both techniques are equally effective, particularly if multiple field plans are used. Taking into account realistic beam and scanning parameters for the Varian ProBeam system, and based on realistic and variable breathing patterns in different liver cases, our results indicate that re-scanning is a viable motion mitigation technique for this system, particularly if layered re-scanning is used. Purpose/Objective: In-room kV imaging is widely applied for intrafraction motion compensation in image-guided radiation therapy (IGRT). The low contrast of lung tumours in kV images and the overlap of high-intensity surrounding structures, such as the mediastinum, may limit the applicability of IGRT techniques in lung cancer treatments. The aim of this study is to apply a CT-based contrast enhancement method to improve markerless lung tumour tracking in kV images, thus enhancing the potential of X-raybased image guidance in lung cancer patients.
OC-0549 Improving the clinical applicability of markerless lung tumour tracking with contrast-enhanced kV imaging

Materials and Methods:
The contrast enhancement technique, previously proposed for cone-beam CT [1] and proton radiography [2] , consists in subtracting to the original image a digital reconstructed radiograph (DRR) obtained by masking out the tumour from the planning CT volume. The target position is identified in the resulting contrastenhanced (CE) image through template matching, by using as template the projection of the CT tumour volume. The application of the contrast enhancement technique to kV imaging was tested on a clinical dataset of lung cancer patients acquired with the CyberKnife Xsight Lung Tracking System (XLTS). The dataset include two patients (P1-P2) treated in three XLTS fractions and four patients (P3-P6) simulated with the XLTS but not treated, since the tumour was not visible in the stereoscopic kV images. A breath-hold CT scan was collected for each patient and five kV images per view were selected for each treatment fraction and simulation, considering for patients P1-P2 the images with the highest XLTS detection confidence. Results: As shown in Figure 1 , the contrast enhancement method allows tumour localization for all patients except P6, for whom the different diaphragm position in the breath-hold DRR and Live kV images hindered tumour visibility. The Michelson contrast [2] between the tumour and the surrounding structures was increased in the CE images by a factor of at least 2.2 compared to the Live images (Table 1) . The median value of the ratio between the tumor contrast in CE images and in Live images was 4.9 and 8.6 for the lung and mediastinum background regions, respectively. For patients P1-P2, the absolute difference in the bidimensional tumour position identified with the XLTS and with the contrast enhancement technique ranged between 0.4 and 1.6 mm, with a median value of 1.2 and 1.0 mm for the horizontal and vertical image directions, respectively.
